Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cancer susceptibility 18 (non-protein coding) (CASC18)
- Target
- CASC18
- Molecular classification
- Long non-coding RNA (lncRNA), Other (does not fit into standard protein-based families such as receptor, enzyme, etc.)
01
Overview
Cancer susceptibility 18 (CASC18), also known as LOC101929110, is a long non-coding RNA (lncRNA) gene with no known protein coding function. CASC18 has been implicated in the regulation of gene expression in cancer, particularly by acting as a competing endogenous RNA (ceRNA) that sponges microRNAs such as miR-5586-5p, thereby influencing the levels of target genes involved in cell invasion, migration, and the epithelial-mesenchymal transition in cancers like cervical squamous cell carcinoma. CASC18 also demonstrates altered expression in cancer and may serve as a biomarker for disease progression or therapeutic response (for example, its upregulation by capecitabine in colorectal cancer cells). While CASC18 is of biological and potential clinical interest as a noncoding RNA regulator in cancer, it is not a direct therapeutic target like a receptor or enzyme.
- Other names
- LOC101929110cancer susceptibility 18 (non-protein coding)cancer susceptibility candidate 18 (non-protein coding)CASC18
02
Mechanism of action
Not applicable for classic drug-target interactions since CASC18 is a noncoding RNA. Regulation via ceRNA axis: acts as a microRNA sponge (e.g., for miR-5586-5p) affecting the expression of downstream genes (such as NUAK1).
03
Biological functions
Regulation of gene expressionCompeting endogenous RNA (ceRNA)/microRNA spongeRegulation of cell migration and invasion via specific miRNA pathwaysPotential modulation of epithelial-mesenchymal transition (EMT) in cancerOther (lncRNAs often exert complex regulatory roles)
04
Disease associations
Cancer (notably in cervical squamous cell carcinoma and colorectal cancer, based on modulation of cancer-related processes by lncRNA-mediated mechanisms)Other (lncRNAs can have diverse disease associations, but cancer is predominant for CASC18)
05
Safety considerations
No specific safety concerns described related to targeting or manipulating CASC18, but as a noncoding RNA, therapeutic modulation could carry risks common to RNA-targeting strategies (off-target effects, delivery challenges)
06
Interacting drugs
Capecitabine (chemotherapy agent shown to increase CASC18 expression in colorectal cancer cell lines)
1 more in the full profile.
07
Biomarkers
CASC18 expression reported as a candidate biomarker in colorectal and other cancers, specifically for prognostic and potentially predictive purposes
Beyond the preview
Go deeper on Cancer susceptibility 18 (non-protein coding) (CASC18).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cancer susceptibility 18 (non-protein coding) (CASC18).